Skip To Content
Course

SARS-CoV-2: Mutations and Variants and Strains (Oh My!)

Ended Feb 17, 2022
1 CEU

Full course description

NETEC COVID-19 Webinar Series

SARS-CoV-2: Mutations and Variants and Strains (Oh My!)

Release Date: 02/18/2021

Expires: 02/17/2022

CID: 49987

The estimated time to complete this enduring material is 60 minutes.

TARGET AUDIENCE

This enduring material is intended primarily for healthcare workers and teams which may include but are not limited to, medical and nursing staff, administration, education/training leadership, and infection control leadership. Staff specializing in emergency management, communications, specialized clinical areas, laboratory, facilities management and environmental services are also welcome.

EDUCATIONAL OBJECTIVES

At the conclusion of this enduring material, the participant should be better able to:

  • Define mutation and variant as they relate to SARS-CoV-2
  • Discuss the importance of the current variants and mutations including future predictions surrounding the epidemiology of spread and modeling
  • Describe what is known about SARS-CoV-2 variants’ susceptibility to vaccines and therapeutic antibodies

REQUIREMENTS FOR SUCCESSFUL COMPLETION

In order to receive continuing education credit, you must complete these steps prior to the activity expiration date.

  1. View the entire presentation
  2. Complete the post-test with a score of 2 out of 3 or better
  3. Complete the online evaluation
  4. Submit the Completion Attestation

ACCREDITED CONTINUING EDUCATION

logo In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and NETEC. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour.  Nurses should only claim credit for the actual time spent participating in the activity.

DISCLOSURE INFORMATION

 

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

 

All faculty, planners and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

 

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

 

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

DISCLOSURES

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:  

FACULTY

James Lawler, MD, MPH

Advisory Committee/Board: Carecubes Inc., Kinsa Health, Takeda Pharmaceuticals US
Stock/Ownership: Carecubes Inc., Kinsa Health

The below faculty have nothing to disclose:

Anne Piantadosi, MD, PhD
Radu Postelnicu, MD

PLANNING COMMITTEE 

The below planning committee members have nothing to disclose:
Sarah Anderson-Fiore, MPH, CHES
Sonia Bell, BS
Valeta Creason-Wahl, HMCC
Heidi Keeler, PhD, RN
Allison Klajbor, BS
Benjamin Mattson, MS Ed
Jason Noble, BA, BFA
Renee Paulin, MSN, RN, CWOCN
Brenda Ram, CMP, CHCP
Michelle Schwedhelm, MSN, RN, NEA-BC
Patricia Tennill, BSN, RN
Sharon Vanairsdale, DNP, APRN, ACNS-BC, NP-C, CEN. FAEN, FAAN
Sami Vasistha, MS

 

FINANCIAL SUPPORT 

This program is funded by ASPR & CDC